K-62

K-62 is a potent and selective small molecule inhibitor of diacylglycerol acyltransferase 1 (DGAT1), an enzyme that catalyzes the final step in the synthesis of triglycerides. Developed by Kowa Company, K-62 was primarily investigated for its potential in treating metabolic disorders, including obesity, type 2 diabetes, and dyslipidemia. By inhibiting DGAT1, the drug aims to reduce the absorption of dietary fats in the intestine and decrease the accumulation of triglycerides in the liver and adipose tissue. Preclinical studies demonstrated that K-62 could improve insulin sensitivity and reduce body weight gain in animal models of metabolic syndrome. Although it showed promise in early development, clinical progress appears to have stalled, and it is no longer a primary focus in the developer's active pipeline.